Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30285752 | 0.76 | P2RX4 (0.39) | HRH4KMT2AALDH1A1PIK3C3 | |
| SCHEMBL26186424 | 0.76 | P2RX4 (0.39) | HRH4KMT2AALDH1A1PIK3C3 | |
| SCHEMBL26186755 | 0.73 | PIK3CA (0.34) | HRH4KDM4CALDH1A1 | |
| SCHEMBL26186724 | 0.68 | TSHR (0.42) | HRH4ALDH1A1HDAC6 | |
| SCHEMBL26186428 | 0.67 | P2RX4 (0.40) | HRH4HSD17B10ALDH1A1PIK3C3 | |
| SCHEMBL30285744 | 0.67 | P2RX4 (0.40) | HRH4HSD17B10ALDH1A1PIK3C3 | |
| SCHEMBL26186730 | 0.66 | HRH4 (0.39) | HRH4 | |
| SCHEMBL30285863 | 0.64 | P2RX4 (0.40) | HRH4HSD17B10ALDH1A1 | |
| SCHEMBL26186420 | 0.64 | P2RX4 (0.40) | HRH4HSD17B10ALDH1A1 | |
| SCHEMBL26186397 | 0.63 | TSHR (0.43) | HRH4KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270729-A1 | USE OF N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY FOR TREATING CERTIAN OCULAR DISORDERS | P2RX2, P2RX4, P2RX5 | HRH4 144/4885KDM5A 4438/4885KDM4C 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.